Stock of the Day

Today's Trend

Scholar Rock Holding Corporation (NASDAQ: SRRK) is receiving several favorable analyst signals following FDA approval for ISEMBYLD, although a small reduction in near-term earnings estimates may temper the reaction. At approximately $49.02, the stock remains below multiple analysts’ $70 price targets.

• FDA approval for ISEMBYLD provides the most significant catalyst. The approval could support commercialization and expand the product’s potential market opportunity, giving investors a clearer path toward future revenue growth. Scholar Rock Holding Wins FDA Approval for ISEMBYLD
• Analyst sentiment has strengthened. Jefferies upgraded Scholar Rock to “strong buy,” while Piper Sandler initiated or reiterated a “buy” recommendation. Wedbush also reaffirmed its “outperform” rating. These actions indicate growing confidence in ISEMBYLD and the company’s longer-term outlook. Jefferies Upgrades Scholar Rock Scholar Rock Receives a Buy from Piper Sandler Wedbush Reaffirms Outperform Rating
• HC Wainwright raised its longer-term earnings forecasts. Estimates improved for fiscal 2027 through 2030, including a reduction in the projected 2027 loss, a narrower 2028 loss, and higher projected profits in 2029 and 2030. The firm maintained a $70 price target and “buy” rating, implying substantial potential upside from the current level.
• Near-term profitability remains limited. HC Wainwright slightly reduced its fiscal 2026 EPS forecast to a $3.30 loss from a $3.29 loss. Scholar Rock is still expected to report losses in the current year, so investors must weigh near-term cash burn against the potential benefits of ISEMBYLD commercialization. Scholar Rock Fair Value Edges Higher